MedPage Today on MSN21h
TYK2 Inhibitor Scores Two Wins Outside Plaque PsoriasisThe TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
MedPage Today on MSN1d
Rapid, Substantial Psoriasis Improvement With Oral IL-23 InhibitorTwo-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...
Verywell Health on MSN10d
Understanding Scalp Psoriasis and How to Treat ItScalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...
Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...
Verywell Health on MSN11d
How to Tell If You May Have Scalp Psoriasis vs. DandruffScalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback